Table 4.
Effect of selected peptides incorporated into bone cement on the prevention of microbial adhesion and consequent biofilm formation on its surface.
| Microbe | CFU/Implant | |||
|---|---|---|---|---|
| Palacos®r without Peptide | Palacos®r with Peptide No | Palacos®r with Antibiotic or Antimycotic | ||
| MRSA 6271 | 6.0 × 104 | (VI) 0 | N/A | |
| MRSA 6271 | 2.0 × 106 | (VI) 8.6 × 101 | N/A | |
| MRSA 6271 | 6.9 × 104 | (IX) 0/(IX) 0 | Vancomycin | 6.9 × 104 |
| *MRSA 6271 | 3.3 × 105/1 × 106 | (VI) 1.4 × 102/(VI) 0 | N/A | |
| MRSA a | 7.0 × 106 | (IV) 0/(IV) 0 | N/A | |
| MRSA a | 8.8 × 103 | (IX) 0/(IX) 0 | N/A | |
| MRSA b | 7.5 × 106/3.5 × 106 | (VI) 2.5 × 102/(VI) 1.0 × 101 | N/A | |
| *MRSA b | 1.2 × 105/0.6 × 105 | (I) 0/(I) 0 | Vancomycin | 4.0 × 106 |
| S. e. | 6.0 × 104/3.2 × 103 | (VI) 4.0 × 102/(VI) 0 | N/A | |
| E. f. | 2.9 × 105 | (I) 0/(I) 0 | N/A | |
| *E. f. | 2.8 × 106 | (I) 0 | Vancomycin | 4.0 × 106 |
| P. a. 5482 | 1.6 × 106/4 × 106 | (I) 5 × 101/(I) 4 | N/A | |
| C. albicans c | 4.4 × 105 | (VIII) 6.0 × 103 | Fluconazole | 3.6 × 104 |
| C. albicans d | 6.0 × 103 | (I) 4.0/(I) 0/(IX) 3.4 × 102 | N/A | |
| C. albicans d | 5.4 × 104/1 × 105 | (VIII) 0/(VIII) 0 | Amphotericin B | 0 |
| * C. tropicalis | 3.7 × 105 | (I) 0/(I) 4.0 | Amphotericin B | 1.3 × 106 |
| C. glabrata | 1.3 × 106 | (VIII) 2.4 × 103 | Clotrimazole | 1.2 × 106 |
Each row represents the result of single experiment performed on one femoral head; a Clinical isolates from Liberec Regional Hospital; b Clinical isolates from University Hospital in Motol, Prague; c ATCC MYA-2876; d F7-39/IDE99; /Two implants in the same bone sample. * In this experimental setup, cements were implanted inside infected holes. In remaining cases, microbes were pipetted into the hole made between the cement implants (placed into non-infected holes) from which they infiltrated towards the implants (see experimental part); N/A, not applied.